{"filings":[{"id":721798,"accession_number":"0001193125-26-245203","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-05-28T20:05:43+00:00","items":["5.07"],"status":"ready","headline":"Teva shareholders re-elect Sol J. Barer to board, approve advisory pay vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Sol J. Barer elected to board with 627.8M for, 245.9M against, 0.5M abstain (broker non-votes 50.7M).","Non-binding advisory compensation proposal passed with 796.0M for, 77.1M against, 1.2M abstain.","Kesselman & Kesselman (PwC) ratified as independent auditor for 2027 with 880.5M for, 36.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99041,"accession_number":"0001171843-26-002796","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).","Key innovative brands: AUSTEDO $578M (+41% YoY), AJOVY $196M (+35%), UZEDY $63M (+62%).","Generics down 16% LC due to lenalidomide competition and Japan BV divestiture.","Acquired Emalex Biosciences for $700M upfront + up to $200M milestones + royalties; ecopipam (Tourette) NDA-ready; close expected Q3 2026.","2026 outlook maintained; Non-GAAP diluted EPS $1.91-$2.11 (stand-alone $2.57-$2.77)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114838,"accession_number":"0001171843-26-000462","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.","Key innovative brands AUSTEDO ($2.26B, +34% YoY), AJOVY ($673M, +30%), UZEDY ($191M, +63%) drove 35% YoY growth.","Non-GAAP operating income margin 28.4% (vs 26.2% in 2024); free cash flow $2,396M.","Gross debt reduced to $16.8B, net debt to $13.3B; credit ratings upgraded by three agencies in 2025.","2026 outlook: revenues $16.4-16.8B, non-GAAP diluted EPS $2.57-2.77, free cash flow $2.0-2.4B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1500000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114837,"accession_number":"0001171843-26-000174","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).","Diluted EPS $2.55-$2.65 (higher end); free cash flow $1.6-$1.9B (higher end).","Duvakitug milestones expected to add $500M revenue and ~$400-430M adjusted EBITDA.","2027 targets: low-single-digit revenue growth, 30% operating margin, FCF >$2.7B, net leverage <2x.","2030 targets: mid-single-digit CAGR, >30% operating margin, FCF >$3.5B, cumulative savings $700M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1500000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131224,"accession_number":"0001193125-25-316063","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.","Maximum leverage ratio set at 4.25x for Q4 2025 and thereafter; can increase 0.5x for acquisitions over $250M.","Covenants suspended if Teva achieves Investment Grade Status (Baa3/BBB- from two agencies); reinstated on loss or default.","Consent fee of 0.08% of total commitments paid to lenders approving the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131223,"accession_number":"0001171843-25-007000","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).","Austedo revenue $618M (+38% YoY); 2025 outlook raised to $2.05B-$2.15B (from $1.95B-$2.05B).","Non-GAAP operating margin 28.9% (+86 bps YoY); on track for 30% target by 2027.","Exclusive TAPI sale discussions terminated; renewed sales process initiated; divestiture intent maintained.","Full-year 2025 non-GAAP EPS guidance raised to $2.55-$2.65 (midpoint +$0.025); FCF unchanged $1.6B-$1.9B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":12547000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147813,"accession_number":"0001171843-25-004808","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).","AUSTEDO global revs $498M (+19% LC), AJOVY $155M (+31% LC), UZEDY $54M (+120% YoY).","Raised 2025 revenue outlook: AUSTEDO $2,000-2,050M, AJOVY $630-640M, UZEDY $190-200M.","Non-GAAP operating margin 27.1% (vs 25.3% Q2 2024); adjusted EBITDA $1,233M (+6%).","Free cash flow $476M (+47% YoY); on track for $700M net savings by 2027 from Transformation programs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":8067000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166515,"accession_number":"0001193125-25-135942","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Teva shareholders elect board, approve executive compensation and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chen Lichtenstein elected to board until 2027; Amir Elstein, Roberto Mignone, Perry Nisen, Tal Zaks elected until 2028.","Non-binding advisory vote on executive compensation approved with 688.8M for vs 99.2M against.","Amended compensation policy for executives and directors approved with 710.2M for.","Reappointment of Kesselman & Kesselman (PwC) as auditor approved with 820.2M for.","All proposals passed with substantial majorities; no material dissent reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166514,"accession_number":"0001193125-25-129488","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.","Net proceeds fund tender offer for up to $2.25B (upsized from $2B) and repay other outstanding debt.","Notes are senior unsecured obligations guaranteed by Teva; customary covenants and events of default.","Issuance made under Teva's existing shelf registration statement filed February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166513,"accession_number":"0001193125-25-125071","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Teva prices $2.3B multi-tranche senior notes offering to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Upsized offering from $2B to ~$2.3B equivalent across three tranches.","€1B 4.125% due 2031 (priced 99.349%), $500M 6.000% due 2032 (99.256%), $700M 5.750% due 2030 (99.418%).","Settlement expected May 28, 2025, subject to customary closing conditions.","Proceeds to fund tender offers for existing notes with coupons 3.15%-8.125% maturing 2026-2031.","Net proceeds may also be used for debt repayment at maturity, tender, or redemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166512,"accession_number":"0001171843-25-002849","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).","Key innovative products grew ~39% YoY: AUSTEDO $411M (+39%), AJOVY $139M (+26%), UZEDY $39M.","FY2025 guidance raised: Non-GAAP EPS $2.45-$2.65 (midpoint +$0.10), Non-GAAP op income $4.3-$4.6B (+$200M at low end).","Generics grew in all regions (U.S. +5%, Europe +1%, Intl +2% in local currency).","On track for 30% operating margin by 2027; announces $700M net savings program."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":3891000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183938,"accession_number":"0001171843-25-000493","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.","Non-GAAP diluted EPS $2.49, down from $2.56; adjusted EBITDA $4.78B.","Key product revenues: AUSTEDO >$1.6B, AJOVY $507M (+18% local), UZEDY $117M.","Generics grew 15% in U.S., 6% in Europe, 15% in International Markets (local currency).","FY2025 outlook: revenue $16.8-$17.4B, non-GAAP EPS $2.35-$2.65, free cash flow $1.6-$1.9B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":16544000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200533,"accession_number":"0001193125-24-256014","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teva elects Chen Lichtenstein to board effective Dec 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chen Lichtenstein elected as independent director, effective Dec 1, 2024, until 2025 annual meeting.","Lichtenstein was CFO of Syngenta Group (2020-2023) and previously CEO of ADAMA Ltd.","He holds a Ph.D. in Business Administration from Stanford and multiple degrees from Hebrew University.","Compensation will be the same as Teva's other non-executive directors.","No material related-party transactions or family relationships with Teva executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200532,"accession_number":"0001171843-24-006034","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.","Austedo US revs $435M (+28%); AJOVY global $137M (+21% local); Uzedy US $35M, FY outlook raised to ~$100M.","Generics up 30% US, 8% Europe, 13% Int’l Markets (local currency); biosimilar to Prolia accepted by FDA/EMA.","FY2024 guidance raised: rev $16.1-16.5B, Adj EBITDA $4.7-5.0B, Non-GAAP EPS $2.40-2.50.","GAAP net loss $437M from $600M goodwill impairment and $450M legal provisions; cash from ops $693M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":12315000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216547,"accession_number":"0001171843-24-004270","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.","Generics grew 16% US, 8% Europe, 22% International; AUSTEDO US revenue $407M (+32%).","Raised 2024 guidance: revenue $16.0-16.4B, non-GAAP EPS $2.30-2.50, adj. EBITDA $4.6-5.0B.","Pipeline: duvakitug top-line now Q4 2024; olanzapine LAI positive Phase 3; SIMLANDI launch.","Free cash flow $324M; $506M tax hit from Israeli Tax Authority settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":7983000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236198,"accession_number":"0001193125-24-167489","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Teva settles Israeli tax dispute for ~$750M over 2008-2020, plus up to $500M contingent","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Teva to pay ~$750M to Israeli Tax Authorities over 2024-2029 for tax years 2008-2020.","Includes ~$500M corporate taxes on previously tax-exempt earnings under Encouragement for Capital Investment Law.","Additional ~$250M for other disputed tax issues in the same period.","Contingent payment of 5%-7% of future dividends/repurchases, capped at ~$500M.","Settlement ends litigation with ITA over historical tax years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236197,"accession_number":"0001193125-24-156043","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Teva shareholders elect four directors, approve say-on-pay and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Prof. Varda Shalev to board through 2026; Rosemary Crane, Gerald Lieberman, Prof. Ronit Satchi-Fainaro through 2027.","Non-binding advisory vote on executive compensation approved: 571,822,049 for vs 120,609,632 against.","Shareholders recommended annual advisory vote on exec comp (one-year frequency) with 536,980,720 votes.","Ratification of Kesselman & Kesselman (PwC) as independent auditor approved: 731,150,255 for, 30,335,560 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236196,"accession_number":"0001193125-24-138936","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teva appoints Matthew Shields as EVP Global Operations; Eric Drapé departs after 11 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Shields becomes EVP Global Operations effective June 3, 2024, based in Parsippany, NJ.","Shields previously SVP Manufacturing at Merck Animal Health; prior roles at Sanofi and Amgen.","Initial base salary of $825,000 with 100% target annual cash incentive, equity awards, and $200,000 sign-on cash.","Eric Drapé leaves Teva after 11 years, including over 4 years as EVP Global Operations.","Shields reports directly to CEO Richard Francis as part of the Pivot to Growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236195,"accession_number":"0001193125-24-133759","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.","AUSTEDO U.S. sales up 67% YoY; AJOVY $113M (+18% YoY).","Non-GAAP diluted EPS $0.48 (vs $0.40); GAAP loss per share $0.12 (vs $0.20 loss).","FY2024 guidance reaffirmed: revenue $15.7-16.3B, non-GAAP EPS $2.20-2.50, free cash flow $1.7-2.0B.","Positive Phase 3 efficacy results for olanzapine LAI (TEV-749) for schizophrenia; no PDSS observed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":3819000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}